This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Chemotherapy Remove Immunization Remove Research Laboratories
article thumbnail

Japan grants approvals for Merck’s Keytruda to treat different cancers

Pharmaceutical Technology

SEPTEMBER 28, 2022

The approvals include Keytruda plus chemotherapy as neoadjuvant treatment and then continued as a single agent for adjuvant treatment post-surgery in hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. This approval is based on KEYNOTE-564 trial data.

Chemotherapy 59
Chemotherapy Research Laboratories Immunity Immunization 59
article thumbnail

Keytruda approved as first-line advanced cervical cancer therapy

pharmaphorum

OCTOBER 14, 2021

Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1. Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system.

Chemotherapy 45
Chemotherapy Research Laboratories Immunity Immunization 45
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 11,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024